ArticleTranslational gastroenterology and hepatology2026
Global research trends on the gut microbiota and immunotherapy for colorectal cancer: a bibliometric analysis.
Article in Translational gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The gut microbiota (GM) plays a critical role in colorectal cancer (CRC) immunotherapy and has attracted considerable scholarly attention in recent years. However, no bibliometric analyses on this topic have been reported to date. To elucidate the current research landscape and guide future studies, we conducted a comprehensive and multidimensional bibliometric analysis of literature from 2014 to 2024. Methods: Publications on GM and CRC immunotherapy spanning 2014-2024 were retrieved from the Web of Science (WoS) core collection and analyzed and visualized using CiteSpace, VOSviewer, and Scimago Graphica. Results: Over the past decade, the WoS core collection (WoSCC) has indexed 325 publications related to GM and CRC immunotherapy, involving 45 countries and regions, 604 institutions, and 2,206 authors. Within the top 20 most productive countries/regions, China accounts for 47% of the total output, significantly surpassing all other nations. The most prolific institution is Shanghai Jiao Tong University (N=14,471 citations; 33.64 citations per article). Among the top ten authors in terms of productivity, seven are based in China. Frontiers in Immunology has the highest publication count in this field (21 articles, accounting for 6.5%). Analysis of the most-cited literature, citation bursts, and keywords highlights a strong association between the GM and the efficacy of immunotherapy for CRC. Certain bacterial species, such as Conclusions: The relationship between GM and immunotherapy for CRC remains in the exploratory and validation stages, with a mature framework for clinical translation yet to be established. This bibliometric analysis maps the current research landscape, identifies emerging hotspots, and suggests that the field is moving toward translational application. However, unresolved causality, limited biomarker reproducibility, insufficient methodological standardization, and the lack of well-designed CRC-specific clinical trials remain major barriers to clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.